Vytrus Biotech sells Vitrus, a proprietary plant-cell and biotech platform used for cosmetic actives and nutraceutical ingredients, which makes its revenue more like specialty ingredient sales than drug development. The 91% gross margin and 33% operating margin suggest the platform earns its keep, and a 32.9% ROE on a 113M EUR market cap shows the company turning equity into profit efficiently. Revenue growth of 52.6% is the number that gets our attention, but the next step is to confirm whether it reflects repeatable customer wins or a lumpy order cycle. On the valuation side, a forward P/E of 25.3 against a trailing 36.6 implies earnings are expected to climb sharply, which is worth testing against the order book and capacity. Small size, no index membership, and a thin-liquidity profile mean this is a name to diligence carefully before any position is considered.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 23 Oct 2026, 01:53 CEST | ACCE price target | €16.50 | first publication | €15.00 |
| 22 Oct 2026, 13:04 CEST | Rating | Overvalued | first publication | €14.60 |
| 22 Oct 2026, 13:04 CEST | Fair value | €8.25 | first publication | €14.60 |
Answered from Vytrus Biotech, S.A. fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| VYT.MC Vytrus Biotech, S.A. | €15.10 | €8 | 83% above | 27.5x | 32.9% | 100 | 68 |
| ZEAL.CO Zealand Pharma A/S | kr 226.00 | - | - | 5.8x | 16.3% | 90 | 51 |
| BIOA-B.ST BioArctic AB (publ) | kr 300.00 | kr 259 | 16% above | 254.2x | 5.2% | 62 | 38 |
| BAVA.CO Bavarian Nordic A/S | kr 247.40 | kr 257 | 4% below | 12.7x | 12.2% | 86 | 86 |
| CAMX.ST Camurus AB (publ) | kr 666.00 | kr 325 | 105% above | 58.8x | 15.9% | 90 | 55 |
| BIOCON.NS Biocon Limited | ₹323.50 | - | - | 97.7x | - | 67 | 52 |
| KRYS Krystal Biotech Inc. Common Stock | $311.50 | $153 | 104% above | 40.1x | 20.1% | 95 | 71 |
Where VYT.MC ranks against its sector peers on each metric.